MX2015012736A - 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas. - Google Patents

2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas.

Info

Publication number
MX2015012736A
MX2015012736A MX2015012736A MX2015012736A MX2015012736A MX 2015012736 A MX2015012736 A MX 2015012736A MX 2015012736 A MX2015012736 A MX 2015012736A MX 2015012736 A MX2015012736 A MX 2015012736A MX 2015012736 A MX2015012736 A MX 2015012736A
Authority
MX
Mexico
Prior art keywords
cancer
aminopyrimidin
ones
proliferative activities
analogs exhibiting
Prior art date
Application number
MX2015012736A
Other languages
English (en)
Other versions
MX365574B (es
Inventor
Michael D Kaufman
Daniel L Flynn
Yu Mi Ahn
Lakshminarayana Vogeti
Timothy Malcolm Caldwell
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Publication of MX2015012736A publication Critical patent/MX2015012736A/es
Publication of MX365574B publication Critical patent/MX365574B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)

Abstract

Se describen compuestos de Fórmula I (ver Fórmula) que son útiles para el tratamiento del cáncer, enfermedades autoinmunitarias y trastornos óseos metabólicos a través de la inhibición de cinas c-FMS (CSF-1R), c-KIT y/o PDGFR; estos compuestos también son útiles para el tratamiento de otras enfermedades de los mamíferos mediadas por cinasas c-FMS, c-KIT o PDGFR.
MX2015012736A 2013-03-15 2014-03-14 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas. MX365574B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792812P 2013-03-15 2013-03-15
PCT/US2014/029661 WO2014145025A2 (en) 2013-03-15 2014-03-14 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities

Publications (2)

Publication Number Publication Date
MX2015012736A true MX2015012736A (es) 2016-05-31
MX365574B MX365574B (es) 2019-06-06

Family

ID=51529950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012736A MX365574B (es) 2013-03-15 2014-03-14 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas.

Country Status (18)

Country Link
US (1) US9181223B2 (es)
EP (1) EP2968286B1 (es)
JP (6) JP6165314B2 (es)
KR (4) KR20240013846A (es)
CN (2) CN105120864B (es)
AU (5) AU2014233411B2 (es)
BR (1) BR112015022288B1 (es)
CA (1) CA2903285C (es)
DK (1) DK2968286T3 (es)
ES (1) ES2651165T3 (es)
HK (1) HK1220398A1 (es)
IL (4) IL241000B (es)
MX (1) MX365574B (es)
PH (1) PH12015502114A1 (es)
PT (1) PT2968286T (es)
RU (1) RU2015143717A (es)
SG (1) SG11201507660TA (es)
WO (1) WO2014145025A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US9181223B2 (en) * 2013-03-15 2015-11-10 Deciphera Pharmaceuticals, Llc 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
AR109179A1 (es) * 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
JP6967302B2 (ja) * 2017-05-24 2021-11-17 アビスコ セラピューティクス カンパニー リミテッド アザアリール誘導体、その製造方法および薬学上の応用
CN110461841B (zh) * 2017-06-19 2020-09-15 上海和誉生物医药科技有限公司 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用
CA3089630A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
CN110845476B (zh) * 2018-08-21 2022-11-18 上海和誉生物医药科技有限公司 一种高选择性csf1r抑制剂、其制备方法和在药学上的应用
EP3902547B1 (en) * 2018-12-28 2023-09-20 Deciphera Pharmaceuticals, LLC Csf1r inhibitors for use in treating cancer
CN114072397A (zh) 2019-05-10 2022-02-18 德西费拉制药有限责任公司 杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法
EP4342469A3 (en) 2019-05-10 2024-06-19 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
CN114258318B (zh) 2019-06-17 2024-09-20 德西费拉制药有限责任公司 氨基嘧啶酰胺自噬抑制剂及其使用方法
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
DK4084778T3 (da) 2019-12-30 2023-12-11 Deciphera Pharmaceuticals Llc Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf
KR20230121758A (ko) 2020-11-18 2023-08-21 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나제 억제제 및 그의 사용 방법
CN115385896A (zh) * 2021-05-24 2022-11-25 上海和誉生物医药科技有限公司 一种csf-1r抑制剂中间体或其酸式盐的制备方法
CN113880812A (zh) * 2021-11-17 2022-01-04 上海皓元生物医药科技有限公司 一种csf-ir抑制剂的制备方法
CN118434727A (zh) * 2021-12-31 2024-08-02 上海海雁医药科技有限公司 取代的嘧啶酮衍生物、其药物组合物及医药上的用途
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046216A1 (en) * 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
AU2007338792B2 (en) * 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
EA201170627A1 (ru) * 2008-10-29 2011-10-31 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Циклопропанамиды и аналоги, проявляющие противораковые и антипролиферативные активности
US9181223B2 (en) * 2013-03-15 2015-11-10 Deciphera Pharmaceuticals, Llc 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
US9193719B2 (en) * 2013-03-15 2015-11-24 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
US9133183B2 (en) 2013-03-15 2015-09-15 Deciphera Pharmaceuticals, Llc Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities

Also Published As

Publication number Publication date
AU2020205294B2 (en) 2022-03-17
AU2022204166B2 (en) 2024-02-15
CN107311981B (zh) 2020-05-29
JP7169412B2 (ja) 2022-11-10
IL275422A (en) 2020-08-31
PT2968286T (pt) 2017-12-12
IL289629B2 (en) 2023-08-01
EP2968286A4 (en) 2016-09-14
KR102399891B1 (ko) 2022-05-20
CN107311981A (zh) 2017-11-03
CN105120864A (zh) 2015-12-02
JP2019094350A (ja) 2019-06-20
PH12015502114B1 (en) 2016-01-25
IL260502B (en) 2020-07-30
BR112015022288B1 (pt) 2022-06-21
DK2968286T3 (en) 2018-01-02
KR20210107143A (ko) 2021-08-31
WO2014145025A3 (en) 2015-01-08
MX365574B (es) 2019-06-06
AU2014233411A1 (en) 2015-09-17
IL289629A (en) 2022-03-01
JP2016521255A (ja) 2016-07-21
AU2022204166A1 (en) 2022-06-30
BR112015022288A2 (pt) 2017-12-19
SG11201507660TA (en) 2015-10-29
WO2014145025A2 (en) 2014-09-18
JP2024105360A (ja) 2024-08-06
AU2022204166C1 (en) 2024-06-20
KR102628583B1 (ko) 2024-01-25
JP2017193567A (ja) 2017-10-26
KR20240013846A (ko) 2024-01-30
IL275422B (en) 2022-02-01
AU2018271293A1 (en) 2018-12-20
JP7536064B2 (ja) 2024-08-19
AU2020205294A1 (en) 2020-08-06
KR102293086B1 (ko) 2021-08-25
HK1220398A1 (zh) 2017-05-05
CN105120864B (zh) 2017-05-17
RU2015143717A3 (es) 2018-03-28
US20140275085A1 (en) 2014-09-18
KR20150128996A (ko) 2015-11-18
JP2021191770A (ja) 2021-12-16
US9181223B2 (en) 2015-11-10
JP2023010738A (ja) 2023-01-20
KR20220070054A (ko) 2022-05-27
PH12015502114A1 (en) 2016-01-25
JP6165314B2 (ja) 2017-07-19
JP6936823B2 (ja) 2021-09-22
IL241000A0 (en) 2015-11-30
IL241000B (en) 2018-07-31
IL289629B1 (en) 2023-04-01
AU2014233411B2 (en) 2018-09-13
RU2015143717A (ru) 2017-04-28
EP2968286B1 (en) 2017-09-13
EP2968286A2 (en) 2016-01-20
ES2651165T3 (es) 2018-01-24
AU2024202088A1 (en) 2024-05-02
AU2018271293B2 (en) 2020-04-16
CA2903285A1 (en) 2014-09-18
CA2903285C (en) 2021-05-11

Similar Documents

Publication Publication Date Title
PH12015502114A1 (en) 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
WO2014145015A3 (en) Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
PH12015502336A1 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
WO2014145029A3 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
MX364486B (es) Derivados de piridazinona-amidas.
MA40076A (fr) Inhibiteurs de syk
PH12015502615A1 (en) Chemical compounds
NZ758528A (en) Bicyclic heterocycle compounds and their uses in therapy
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
MX2017008442A (es) Uso de picolinamidas como fungicidas.
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
PH12016500225B1 (en) Novel quinoline-substituted compound
PH12015502737A1 (en) Novel fused pyrimidine compound or salt thereof
EA201591051A1 (ru) Ингибиторы erk и варианты их применения
EA201400178A1 (ru) Лечение рака молочной железы
EA201890572A1 (ru) Биофармацевтические композиции
NZ730334A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2015008877A (es) Conjugados de disulfuro mixto de compuestos de tienopiridina y sus usos.
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
GEP20186893B (en) Pyrazines modulators of gpr6
MX2017006899A (es) Sintesis de polioles polimericos en polioles insaturados, polioles polimericos y su uso.
IN2013DE02503A (es)

Legal Events

Date Code Title Description
FG Grant or registration